Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 1.00 |
| ▸ | RAF1 | P04049 | 6/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285501 | 0.92 | MET (1.00) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2285936 | 0.91 | MET (1.00) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2290067 | 0.90 | MET (1.00) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2292092 | 0.90 | MET (0.90) | METRAF1DYRK1AMAPK14 | |
| SCHEMBL2288836 | 0.87 | MET (0.82) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2286378 | 0.86 | MET (1.00) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL12414715 | 0.85 | MET (1.00) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2289810 | 0.84 | MET (1.00) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2357439 | 0.84 | MET (0.80) | METRAF1DYRK1AMAPK14MAPK13 | |
| SCHEMBL2292262 | 0.82 | MET (0.78) | METRAF1DYRK1AMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342202-B1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2015-11-11 | — | — | EP | claimed |
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | claimed |
| EP-2342202-B1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2342202-B1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2015-11-11 | — | — | EP | disclosed |
| WO-2010046013-A1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | AZI2, ABL1, RET | MET 8/4885RAF1 281/4885DYRK1A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.